Why Progyny Stock Plunged, Then Gradually Recovered Today
Key Points
Progyny's sales and adjusted earnings per share grew by 5% and 15% in the second quarter.
However, management's conservative guidance for 7% to 11% revenue growth in Q3 worried the market.
Ultimately, everything looked solid, and investors should watch the growth of Progyny's new Select offering going forward.
- 10 stocks we like better than Progyny ›
Shares of fertility benefits management company Progyny (NASDAQ: PGNY) are down 6% on Friday as of 11 a.m. ET, after the company reported second-quarter earnings. Sales rose 5% (11% minus a large client's departure last year), and adjusted earnings per share jumped 15%, outpacing Wall Street's expectations. However, management guidance for Q3 sales to rise only 7% to 11%, along with a slight sequential earnings dip, prompted today's negative market reaction.
I don't think this is bad guidance; it's probably just a bit conservative for a company heading into its busy season. Ultimately, it was a solid Q2 for Progyny as gross profit margins expanded 180 basis points, which is a big deal as the company morphs from a pure-growth stock to more of a profitable compounder (hopefully). Meanwhile, the average number of covered members rose by 7% to 7.2 million, and utilization rates continued to inch higher, suggesting that the company's suite of fertility and women's health solutions remains popular.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
While I'm hesitant to say just how wide Progyny's moat may be, management believes retention rates have been near 100% in 2026, and roughly 30% of clients have increased their buying. Now, Progyny is shifting its focus from companies with more than 1,000 employees to smaller firms with 100 or more employees through its Progyny Select offering. This is a pooled risk model that lets smaller employers participate in Progyny's offerings at a fixed price. This could make the offerings affordable for smaller companies that would previously have been scared off by large one-off costs incurred by their employees in the program.
This Progyny Select offering could provide the next chapter of growth for Progyny if all goes well, so I think the stock will be worth monitoring. Though the stock trades at 35 times free cash flow (after stock-based compensation), management has done a good job offsetting this dilution by lowering its share count by 8% annually over the last three years. Progyny is already a core holding for me, and I may add to my position in the stock again.
Should you buy stock in Progyny right now?
Before you buy stock in Progyny, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Progyny wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $397,405!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,344,091!*
Now, it’s worth noting Stock Advisor’s total average return is 953% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of August 7, 2026.
Josh Kohn-Lindquist has positions in Progyny. The Motley Fool has positions in and recommends Progyny. The Motley Fool has a disclosure policy.
